January
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
February
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
March
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
April
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
May
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
June
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
July
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
August
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
September
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
October
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
November
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
December
PtSaÇaPeCuCtPz
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Olay yoğunluğu:
1-5
6-9
10-12
13+
1998 yılındaki olaylar
—
1998: Trastuzumab (Herceptin): HER2-Targeted Therapy (1998)
Landmark Approval
Trastuzumab demonstrated that an oncogenic driver gene—present in a defined patient subset— could be pharmacologically silenced with a [[term:monoclonal-antibody|monoclonal antibody]], …
—
1998: Sildenafil: Serendipitous PDE5 Discovery (1998)
Landmark Approval
Sildenafil illustrated that rigorous attention to unexpected clinical signals during trials can salvage—and dramatically redirect—a failing programme. It created the …